Abstract: We evaluated intratumoral heterogeneity of 30 ductal breast carcinomas with HER2/neu amplification, scored by the American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) criteria, and 3+ immunoexpression. High-grade (ratio > or =4.0) vs low-grade amplification (ratio >2.2 to <4.0) and chromosome 17 polysomy were also evaluated. On whole tissue sections, 20 tumors (67%) showed high-grade and 10 (33%) showed low-grade HER2/ neu amplification. Of 20 tumors with high-grade amplification, 14 (70%) showed no intratumoral genotypic heterogeneity; 6 (30%) showed at least 1 core with low-grade amplification. Of 10 cases with low-grade amplification, 6 (60%) showed no intratumoral heterogeneity; 4 (40%) showed chromosome 17 polysomy without gene amplification in 2 of 3 cores per case. Of 30 cases with gene amplification, 4 (13%) showed a "not-amplified pattern" in other parts of the tumor. The routine assessment of HER2/neu amplification using the ASCO/CAP criteria on whole tissue sections is not significantly confounded by intratumoral heterogeneity in breast cancer with high-grade amplification; however, genetic heterogeneity exists in a subset of breast carcinomas with low-grade amplification. The clinical relevance and impact on treatment outcome of intratumoral heterogeneity in breast cancer with low-grade HER2/neu amplification or chromosome 17 polysomy need further investigation.

Genotypic Intratumoral Heterogeneity in Breast Carcinoma with HER2/neu Amplification Evaluation According to ASCO/CAP Criteria / Brunelli, Matteo; Manfrin, Erminia; Martignoni, Guido; Miller, K; Remo, Andrea; Reghellin, Daniela; Bersani, Samantha; Gobbo, Stefano; Eccher, Albino; Chilosi, Marco; Bonetti, Franco. - In: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0002-9173. - 131:5(2009), pp. 678-682. [10.1309/AJCP09VUTZWZXBMJ]

Genotypic Intratumoral Heterogeneity in Breast Carcinoma with HER2/neu Amplification Evaluation According to ASCO/CAP Criteria

ECCHER, Albino;
2009

Abstract

Abstract: We evaluated intratumoral heterogeneity of 30 ductal breast carcinomas with HER2/neu amplification, scored by the American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) criteria, and 3+ immunoexpression. High-grade (ratio > or =4.0) vs low-grade amplification (ratio >2.2 to <4.0) and chromosome 17 polysomy were also evaluated. On whole tissue sections, 20 tumors (67%) showed high-grade and 10 (33%) showed low-grade HER2/ neu amplification. Of 20 tumors with high-grade amplification, 14 (70%) showed no intratumoral genotypic heterogeneity; 6 (30%) showed at least 1 core with low-grade amplification. Of 10 cases with low-grade amplification, 6 (60%) showed no intratumoral heterogeneity; 4 (40%) showed chromosome 17 polysomy without gene amplification in 2 of 3 cores per case. Of 30 cases with gene amplification, 4 (13%) showed a "not-amplified pattern" in other parts of the tumor. The routine assessment of HER2/neu amplification using the ASCO/CAP criteria on whole tissue sections is not significantly confounded by intratumoral heterogeneity in breast cancer with high-grade amplification; however, genetic heterogeneity exists in a subset of breast carcinomas with low-grade amplification. The clinical relevance and impact on treatment outcome of intratumoral heterogeneity in breast cancer with low-grade HER2/neu amplification or chromosome 17 polysomy need further investigation.
2009
131
5
678
682
Genotypic Intratumoral Heterogeneity in Breast Carcinoma with HER2/neu Amplification Evaluation According to ASCO/CAP Criteria / Brunelli, Matteo; Manfrin, Erminia; Martignoni, Guido; Miller, K; Remo, Andrea; Reghellin, Daniela; Bersani, Samantha; Gobbo, Stefano; Eccher, Albino; Chilosi, Marco; Bonetti, Franco. - In: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. - ISSN 0002-9173. - 131:5(2009), pp. 678-682. [10.1309/AJCP09VUTZWZXBMJ]
Brunelli, Matteo; Manfrin, Erminia; Martignoni, Guido; Miller, K; Remo, Andrea; Reghellin, Daniela; Bersani, Samantha; Gobbo, Stefano; Eccher, Albino;...espandi
File in questo prodotto:
File Dimensione Formato  
intratumoral.pdf

Accesso riservato

Dimensione 411.34 kB
Formato Adobe PDF
411.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1317419
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 98
  • ???jsp.display-item.citation.isi??? 91
social impact